Proyectos
Estratégicos

Leadership and innovation in cancer immunotherapy in Navarre (LINTERNA)

Treatment of oncology patients has advanced at breakneck speed as a consequence of advances in cancer immunotherapy. Thanks to the use of monoclonal antibodies that disinhibit certain brakes in the immune system, a significant portion of patients become long-term survivors. In Navarre, we have experts in several areas including immunotherapy and preclinical research and clinical practice (clinical trials), as well as pharmaceutical companies that are leaders in stimulating the immune system against cancer.

The LINTERNA project emerged to unify and consolidate the synergetic collaboration between those groups in order to (i) improve immunotherapy treatments using genome techniques, (ii) validate new treatments in experimental models optimising the use of infrastructures, (iii) and promote participation in and carrying out clinical trials for cancer immunotherapy in hospitals in Navarre.

Implementation of precision olfactory medicine and developing nasal immunomodulator therapies in ageing and neurodegeneration

Research done previously in Navarre showed a direct association between the sense of smell and the immune system and its impact on cognitive and motor functions. In an ageing society, we need disruptive approaches that generate innovative tools for detecting and diagnosing neurodegenerative illnesses early. The goal of the INNOLFACT project is to implement the practice of precision olfactory medicine (POM) and develop nasal therapies that modulate the immune system in the brain.

INNOLFACT intends to provide a range of olfactory analyses that offer personalised management of ageing and the associated neurodegenerative diseases in terms of early diagnosis and slowing clinical progression.